-
Mashup Score: 3
The treatments are being described as a “game changer.” A Seattle-area family that has battled the condition, says it brings them hope.
Source: www.king5.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The treatments are being described as a “game changer.” A Seattle-area family that has battled the condition, says it brings them hope.
Source: www.king5.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The treatments are being described as a “game changer.” A Seattle-area family that has battled the condition, says it brings them hope.
Source: www.king5.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Life after sickle cell disease, is it really uhuru? - 5 month(s) ago
Sickle cell disease affects millions of individuals worldwide, causing relentless end-organ injury, episodic emergencies, and early mortality. Deficiencies in sickle cell disease diagnosis, clinical care, treatment, and research are well recognised global health disparities.1 We are entering a long-awaited era when practical, curative therapies for sickle cell disease are on the horizon. Yet opportunities to use potentially curative therapy through haematopoietic cell therapies, including haematopoietic stem-cell transplantation (HSCT) and gene therapy, introduce new risks and uncertainty.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 146
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
Using #genetherapy to treat #sicklecell is a game changer for those living with the disease, says Dr. @KFertrin. "It allows virtually any patient to have a donor because they don't need a match. They can get this treatment using their own stem cells." https://t.co/X6nmf3UA2B